Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in LLY usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 28 extraordinary options activities for Eli Lilly. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 35% leaning bullish and 46% bearish. Among these notable options, 9 are puts, totaling $918,100, and 19 are calls, amounting to $2,223,588.
What's The Price Target?
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $330.0 to $940.0 for Eli Lilly over the recent three months.
Analyzing Volume & Open Interest
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Eli Lilly's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Eli Lilly's whale activity within a strike price range from $330.0 to $940.0 in the last 30 days.
Eli Lilly Option Volume And Open Interest Over Last 30 Days
Biggest Options Spotted:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | CALL | TRADE | BULLISH | 01/17/25 | $17.25 | $16.35 | $17.0 | $780.00 | $850.0K | 3.9K | 519 |
| LLY | PUT | TRADE | NEUTRAL | 12/18/26 | $48.0 | $45.25 | $46.6 | $600.00 | $466.0K | 199 | 100 |
| LLY | CALL | TRADE | BEARISH | 03/21/25 | $13.2 | $12.55 | $12.75 | $900.00 | $277.9K | 940 | 223 |
| LLY | CALL | TRADE | BEARISH | 12/18/26 | $184.0 | $180.5 | $180.5 | $750.00 | $180.5K | 38 | 10 |
| LLY | CALL | TRADE | BEARISH | 12/18/26 | $183.15 | $180.0 | $180.0 | $750.00 | $180.0K | 38 | 20 |
About Eli Lilly
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
In light of the recent options history for Eli Lilly, it's now appropriate to focus on the company itself. We aim to explore its current performance.
Current Position of Eli Lilly
- With a volume of 506,387, the price of LLY is up 0.23% at $779.88.
- RSI indicators hint that the underlying stock may be approaching oversold.
- Next earnings are expected to be released in 34 days.
What The Experts Say On Eli Lilly
In the last month, 1 experts released ratings on this stock with an average target price of $997.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. Click here for access. * In a cautious move, an analyst from B of A Securities downgraded its rating to Buy, setting a price target of $997.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Eli Lilly with Benzinga Pro for real-time alerts.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
